PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 37 filers reported holding PROQR THRAPEUTICS N V in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $0 | – | 200 | 0.0% | 0.00% | – |
Q2 2023 | $0 | – | 200 | 0.0% | 0.00% | – |
Q1 2023 | $0 | -100.0% | 200 | 0.0% | 0.00% | – |
Q4 2022 | $1,000 | – | 200 | 0.0% | 0.00% | – |
Q3 2022 | $0 | – | 200 | 0.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 200 | -99.6% | 0.00% | – |
Q1 2022 | $51,000 | -88.7% | 56,273 | 0.0% | 0.00% | – |
Q4 2021 | $451,000 | -7.6% | 56,273 | -3.4% | 0.00% | – |
Q3 2021 | $488,000 | +31.2% | 58,273 | +5.4% | 0.00% | – |
Q2 2021 | $372,000 | +3.0% | 55,273 | +1.2% | 0.00% | – |
Q1 2021 | $361,000 | +63.3% | 54,608 | +3.8% | 0.00% | – |
Q4 2020 | $221,000 | -13.3% | 52,608 | -1.0% | 0.00% | – |
Q3 2020 | $255,000 | -35.1% | 53,158 | -17.8% | 0.00% | – |
Q2 2020 | $393,000 | +362.4% | 64,658 | +319.8% | 0.00% | – |
Q1 2020 | $85,000 | +400.0% | 15,402 | +782.1% | 0.00% | – |
Q4 2019 | $17,000 | +325.0% | 1,746 | +132.8% | 0.00% | – |
Q3 2019 | $4,000 | +100.0% | 750 | +275.0% | 0.00% | – |
Q2 2019 | $2,000 | -33.3% | 200 | 0.0% | 0.00% | – |
Q1 2019 | $3,000 | 0.0% | 200 | 0.0% | 0.00% | – |
Q4 2018 | $3,000 | -25.0% | 200 | 0.0% | 0.00% | – |
Q3 2018 | $4,000 | +300.0% | 200 | 0.0% | 0.00% | – |
Q2 2018 | $1,000 | -66.7% | 200 | -72.3% | 0.00% | – |
Q1 2018 | $3,000 | 0.0% | 723 | 0.0% | 0.00% | – |
Q4 2017 | $3,000 | -25.0% | 723 | 0.0% | 0.00% | – |
Q3 2017 | $4,000 | +33.3% | 723 | +38.2% | 0.00% | – |
Q2 2017 | $3,000 | 0.0% | 523 | 0.0% | 0.00% | – |
Q1 2017 | $3,000 | 0.0% | 523 | 0.0% | 0.00% | – |
Q4 2016 | $3,000 | 0.0% | 523 | 0.0% | 0.00% | – |
Q3 2016 | $3,000 | 0.0% | 523 | 0.0% | 0.00% | – |
Q2 2016 | $3,000 | -76.9% | 523 | -79.3% | 0.00% | – |
Q1 2016 | $13,000 | +160.0% | 2,523 | +382.4% | 0.00% | – |
Q4 2015 | $5,000 | -37.5% | 523 | 0.0% | 0.00% | – |
Q3 2015 | $8,000 | -11.1% | 523 | 0.0% | 0.00% | – |
Q2 2015 | $9,000 | -18.2% | 523 | -0.2% | 0.00% | – |
Q1 2015 | $11,000 | – | 524 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |